WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma by de Jong, Mathilde R. W. et al.
 
 
 University of Groningen
WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through
induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma
de Jong, Mathilde R. W.; Langendonk, Myra; Reitsma, Bart; Herbers, Pien; Lodewijk,
Monique; Nijland, Marcel; van den Berg, Anke; Ammatuna, Emanuele; Visser, Lydia; van
Meerten, Tom
Published in:
Therapeutic advances in hematology
DOI:
10.1177/2040620719898373
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
de Jong, M. R. W., Langendonk, M., Reitsma, B., Herbers, P., Lodewijk, M., Nijland, M., van den Berg, A.,
Ammatuna, E., Visser, L., & van Meerten, T. (2020). WEE1 inhibition synergizes with CHOP chemotherapy
and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell
lymphoma. Therapeutic advances in hematology, 11, 2040620719898373. [2040620719898373].
https://doi.org/10.1177/2040620719898373
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the





2020, Vol. 11: 1–14
DOI: 10.1177/ 
2040620719898373
© The Author(s), 2020.  
Article reuse guidelines:  
sagepub.com/journals-
permissions
Therapeutic Advances in Hematology
journals.sagepub.com/home/tah 1
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  
(https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
For several decades the first-line treatment for 
diffuse large B-cell lymphoma (DLBCL) has 
consisted of the chemotherapy combination of 
cyclophosphamide, vincristine, doxorubicin and 
prednisone (CHOP) together with the anti-
CD20 antibody rituximab (R), with or without 
radiation therapy (RT).1 Although around 60% 
of DLBCL patients are cured using R-CHOP, 
30–40% will experience disease relapse and 10% 
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Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, 
characterized by high levels of genomic instability and the activation of DNA damage repair 
pathways. We previously found high expression of the cell cycle regulator WEE1 in DLBCL 
cell lines. Here, we investigated the combination of the WEE1 inhibitor, AZD1775, with 
cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) and radiation therapy (RT), 
with the aim of improving first-line treatment.
Methods: Cell viability experiments were performed to determine synergistic combinations. 
Levels of DNA damage were established using flow cytometry for γH2AX and protein analysis 
for DNA damage response proteins CHK1 and CHK2. Flow cytometry analysis for cell cycle 
and pH3 were performed to determine cell cycle distribution and premature mitotic entry.
Results: Treatment with either RT or CHOP led to enhanced sensitivity to AZD1775 in several 
DLBCL cell lines. Treatment of cells with AZD1775 induced unscheduled mitotic progression, 
resulting in abnormal cell cycle distribution in combination with RT or CHOP treatment. In 
addition, a significant increase in DNA damage was observed compared with CHOP or RT 
alone. Of the single CHOP components, doxorubicin showed the strongest effect together with 
AZD1775, reducing viability and increasing DNA damage.
Conclusion: In conclusion, the combination of RT or CHOP with AZD1775 enhances sensitivity 
to WEE1 inhibition through unscheduled G2/M progression, leading to increased DNA 
damage. Based on these results, WEE1 inhibition has great potential together with other G2/M 
arresting or DNA damaging (chemo) therapeutic compounds and should be further explored in 
clinical trials.
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of patients develop primary refractory disease,2 
which has a very poor prognosis. Intensification 
of chemotherapy has not improved survival and 
has only led to greater toxicity.3 Furthermore, 
second generation anti-CD20 antibodies such as 
ofatumumab, veltuzumab or the third generation 
anti-CD20 antibody obinutuzumab have all 
failed to out-perform R in DLBCL.4,5 Novel 
therapies that combine R-CHOP with borte-
zomib,6 lenalidomide7 or ibrutinib8 have not yet 
produced the expected improved responses in 
DLBCL patients. Clearly, there is still an unmet 
need for improvements to first-line therapies for 
a significant number of DLBCL patients. New 
first-line combinations for DLBCL should be 
based on the targeting of unique and specific 
DLBCL proteins and should act synergistically 
with R-CHOP.
We recently identified WEE1 as a promising tar-
get in DLBCL and demonstrated its efficacy as a 
druggable target in combination with rituximab.9 
WEE1 is a cell cycle regulator that inhibits G2/M 
transition by blocking CDC2/CDK1 activity 
through phosphorylation at Tyr15. In the event 
of DNA damage, WEE1 is activated by CHK1 to 
allow DNA damage repair before the cell transi-
tions into mitosis.10 Many tumour cells rely on 
this cell cycle checkpoint for repair because they 
have lost the ability to repair DNA damage at the 
G1/S phase as a result of TP53 abnormalities 
(deletions or mutations) or mutations in other 
cell cycle controlling genes, often resulting in 
diminished activity of the CDK inhibitor p21.11 
In DLBCL, aberrant and off-target activity of 
activation-induced cytidine deaminase induces 
oncogenic mutations and chromosomal translo-
cations,12 causing genetic instability13 and activa-
tion of DNA damage repair pathways.14 In this 
setting, targeting WEE1 could prevent proper 
initiation of the G2/M checkpoint, leading to 
accumulation of DNA damage and mitotic catas-
trophe. Inhibition of WEE1 using AZD1775 has 
been shown to be effective in many different 
tumour types, especially in tumours with com-
promised DNA damage response pathways such 
as TP53-deficient ovarian adenocarcinoma 
tumour cells.15 Since WEE1 inhibition prevents 
adequate DNA damage repair, targeting WEE1 
in cells with an already compromised DNA dam-
age repair pathway or inducing additional DNA 
damage through genotoxic compounds would 
seem a rational application for WEE1 inhibition 
in DLBCL treatment.
Here, we investigated the effect of the WEE1 
inhibitor AZD1775 combined with standard RT 
or CHOP therapy. We observed a synergistic 
effect of AZD1775 with both RT and CHOP, as 
treatment of DLBCL cells with RT or CHOP led 
to increased expression of the DNA damage 
response proteins CHK1 and CHK2, increased 
levels of the DNA damage marker γH2AX and 
increased levels of premature mitotic entry. 
Together, these findings indicate that blocking 
WEE1, in combination with RT or CHOP, limits 
the time necessary for DNA repair due to 
unscheduled mitosis, increases DNA damage and 
ultimately results in enhanced cell death. These 
data indicate the potential of WEE1 inhibition in 
combination with first-line RT and CHOP ther-
apy for DLBCL patients and highlight the clinical 
potential of AZD1775 in DLBCL treatment.
Materials and methods
Cell lines and culture conditions
The DLBCL cell lines U-2932, SUDHL-2, 
SUDHL-4 and SC-1 were cultured in suspen-
sion in Roswell Park Memorial Institute medium 
1640 (RPMI 1640; Lonza BioWhittaker, 
Walkersville, MD, USA) with 10% foetal bovine 
serum (FBS; HyClone Thermo Scientific, 
Waltham, MA, USA), 1% penicillin-streptomy-
cin (PS; Lonza BioWhittaker) and 1% glutamine 
(Lonza BioWhittaker). The DLBCL cell lines 
OCILY3, SUDHL-5, SUDHL-6 and SUDHL-
10 were cultured in suspension in RPMI 1640 
with 20% FBS, 1% PS and 1% glutamine. All 
cell lines were cultured at 37°C with 5% CO2 in 
a humidified atmosphere. The identity of our cell 
lines was regularly checked using short tandem 
repeat typing and their TP53 gene status was 
determined by sequencing exons 1–10.
Compounds and radiation
The WEE1 inhibitor AZD1775 was acquired 
from Selleckchem (No.S1525, Houston, TX, 
USA). RT was performed at a dosage from 2 to 
20 Gy using a Cesium-137 source-662 keV pho-
tons (IBL 637, Cis Bio International, Gif- sur-
Yvette, France) and metabolic activity of cells 
was measured after 72 h. CHOP included cyclo-
phosphamide (University Medical Center 
Groningen [UMCG] pharmacy), doxorubicin 
(No.S1208, Selleckchem), vincristine (UMCG 
pharmacy) and prednisolone (No.S1737, 
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Selleckchem), in a composition set at the clinical 
ratio of 83/5.5/0.16/11.1, respectively.16
Metabolic activity
Metabolic activity of cells was measured after 72 h 
treatment of 0.4 × 106 cells/ml. Cells were incu-
bated with 10 µl resazurin (5% final concentra-
tion, AlamarBlue, Thermo Fisher Scientific, 
Waltham, MA, USA) for 9 h prior to read-out 
(Varioskan, excitation 560 nm, emission 590 nm). 
Experiments were performed five times.
Flow cytometry: cell cycle, γH2AX and pH3 with 
DNA content
For cell cycle analysis, 0.2 × 106 cells/ml were 
treated for the indicated time points, washed 
with 1% bovine serum albumin/phosphate-buff-
ered saline (PBS) and resuspended in solution 
containing 0.1% sodium citrate (A0158348, 
Merck, Kenilworth, NJ, USA), 0.01% propid-
ium iodide (P4170, Sigma-Aldrich, St. Louis, 
MO, USA), 0.002% RNase A (R4875, Sigma-
Aldrich) and 0.3% Triton X100 (T9284, Sigma-
Aldrich). Samples were processed on a BD 
FACSCalibur 2 and analysed with ModFit LT 
(Verity Software House). Experiments were per-
formed three times.
For γH2AX analysis, 0.2 × 106 cells/ml were 
treated for the indicated time points and then 
stained with mouse anti-γH2AX-AlexaFluor-647 
(clone 2F3, #613408, BioLegend) and propidium 
iodide solution (P4170, Sigma) according to the 
protocol provided with the eBioscience Foxp3/
Transcription Factor Staining Buffer Set 
(ThermoFisher, #00-5523-00). Samples were pro-
cessed on a MACSQuant and the data were ana-
lysed using Kaluza 1.5 analysis software (Beckman). 
Experiments were performed three times.
For pH3 analysis, 0.2 × 106 cells/ml were treated 
for the indicated time points and stained with 
mouse-anti-pH3-AlexaFluor-647 (clone 11D8, 
#650806, Biolegend) and propidium iodide 
solution (P4170, Sigma) according to the proto-
col provided with the eBioscience Foxp3/
Transcription Factor Staining Buffer Set 
(ThermoFisher, #00-5523-00). Samples were 
processed on a MACSQuant and data were ana-
lysed using Kaluza 1.5 analysis software 
(Beckman). Premature mitotic cells were identi-
fied as pH3 positive cells measured in S-phase 
instead of in G2/M phase. Experiments were per-
formed three times.
Western blot
Cells were washed with PBS and lysed in radioim-
munoprecipitation assay buffer (50mM Tris, 
150mM NaCl, 2.5 mM Na2EDTA, 1% Triton 
X-100, 0.5%mM sodium deoxycholate, 0.1% SDS 
in dH20) with 1 mM phenylmethanesulphonyl fluo-
ride for 30–45 min on ice. Protein concentration 
was determined using the Pierce BCA Protein 
Assay Kit (#23227; Thermo Scientific, Waltham 
MA, USA). Samples were loaded at 40 µg per lane 
and electrophoresis and blotting was performed 
according to standard protocols. Staining with pri-
mary antibodies for anti-WEE1 (1:200, sc-5285 
(B11), Santa Cruz Biotechnology, Dallas TX, 
USA), anti-phospho-CDC2 (Tyr15) (10A11) 
(1:1000, #4539, Cell Signaling Technology, 
Danvers, MA, USA), anti-phospho-Histone H2AX 
(Ser139) (1:1000, clone JBW301, Merck Millipore, 
Temecula, CA, USA) and GAPDH (1:10,000; 
NovusBio) was done overnight at 4°C.
Statistical analysis
Data were analysed using Graphpad PRISM 
(version 5.0) software and tested for significant 
differences using a paired t-test. Bubble graphs 
were plotted, with the position of each bubble on 
the y-axis representing an IC50 value and the size 
representing the calculated factor differences 
versus the control. The size of each bubble is an 
arbitrary unit, determined by the factor and 
fold change between the combination IC50 
(AZD + treatment) versus AZD alone (=1). This 
is calculated with the formula: 1 (factor of AZD 
alone) *IC50 AZD + treatment ÷ IC50 AZD 
alone. If the IC50 value could not be calculated 
the value is marked with ‘not available’. 
Synergism of combination therapies was calcu-
lated using the method of combination sub-
thresholding, which calculates the difference 
between the expected effect (E) of the combina-
tion therapy compared with the observed effect 
(O) of the combination therapy and tested for 
significant differences using a paired t-test. 
Corresponding significant p-values were colour 
coded to represent additive combinations in 
white (E = O), synergistic combinations in green 
(E < O) and antagonistic combinations in red 
(E > O). * indicates p ⩽ 0.05, ** indicates p ⩽ 0.01 
and *** indicates p ⩽ 0.001.
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Results
Radiation and CHOP therapy enhance sensitivity 
to AZD1775 in DLBCL cell lines
RT and CHOP chemotherapy are part of the stand-
ard treatment for DLBCL and both induce high 
levels of DNA damage thereby causing cell death. 
Efficient DNA damage repair and survival and/or 
resistance require both activation of the DNA dam-
age response and cell cycle arrest. We hypothesized 
that WEE1 inhibition together with RT and CHOP 
prevents cell cycle arrest and allows DNA damage 
to accumulate against a background of repair inhibi-
tion, resulting in enhanced cell killing. Titration of 
AZD1775 in eight DLBCL cell lines revealed a 
wide range of sensitivities to AZD1775, with a mini-
mum IC50 value of 357 nM for OCI-LY3 to a maxi-
mum IC50 value of 1835 nM for SUDHL-4, values 
that are comparable with or less than the clinical 
Cmax serum concentration for AZD1775 of 
1650 nmol/L in solid tumours17 (Supplemental 1a). 
The combination of AZD1775 with RT showed a 
dose-dependent decrease in the IC50 values of all 
cell lines, thereby enhancing sensitivity to AZD1775. 
The combination of RT and AZD1775 was syner-
gistic in six out of eight cell lines (Figure 1a and 
Supplemental 2a). Combination of AZD1775 with 
4 Gy radiation resulted in a 5.5-fold increased sensi-
tivity to AZD1775 (IC50 decrease from 357 nM to 
65 nM) in OCI-LY3. The combination of AZD1775 
together with CHOP chemotherapy gave similar 
results, with a dose-dependent decrease in the IC50 
values of all cell lines, resulting in synergism in seven 
out of eight cell lines (Figure 1b and Supplemental 
2b). An up to 6-fold enhanced sensitivity to 
AZD1775 was observed in SUDHL-10 (IC50 
decrease from 608 nM to 100 nM) (Figure 1b). 
Analysis of the TP53 status of our cell lines revealed 
no correlation between TP53 mutation status and 
IC50 values for AZD1775 (p = 0.2500) (Supplemental 
1b), CHOP (p = 0.5446) (Supplemental 1c) or RT 
(p = 0.1876) (Supplemental 1d) nor the response to 
combination therapy. In conclusion, these results 
demonstrate the great potential of the WEE1 inhibi-
tor AZD1775 in combination with CHOP and RT 
as a first-line standard therapy in DLBCL.
AZD1775 with RT or CHOP therapy activates the 
DNA damage response
Next, we investigated if the synergistic effect of 
WEE1 inhibition together with DNA damaging 
agents (RT or CHOP) was a result of increased 
DNA damage in the representative cell lines 
SUDHL-5, SUDHL-6 and SUDHL-10. Flow 
cytometry analysis of the DNA damage marker 
γH2AX showed a moderate increase in γH2AX 
positive cells (3–13%) after treatment with 
AZD1775 (Figure 2A–B). Similarly, radiation 
alone at the suboptimal dose of 2 and 4 Gy 
induced little DNA damage (5–11% γH2AX pos-
itive cells) (Figure 2a). However, the combina-
tion of RT with AZD1775 led to a dose-dependent 
increase of γH2AX positive cells. In SUDHL-6, 
4 Gy radiation produced 10% γH2AX positive 
cells, increasing to 34% when combined with 
500 nM AZD1775 (p = 0.02) (Figure 2a). 
Treatment with CHOP (Figure 2b) at a subopti-
mal dose of 0.1 µg/ml induced minimal DNA 
damage (5–7% γH2AX positive cells) in all cell 
lines, whereas 1 µg/ml induced significant levels of 
DNA damage (39–54% γH2AX positive cells) in 
DLBCL cell lines. The addition of 500 nM 
AZD1775 to 0.1 µg/ml CHOP significantly 
increased γH2AX positive cells (from 7% to 40%; 
p = 0.0107) in both SUDHL-5 and SUDHL-6 
(5–16%; p = 0.0261). At the CHOP dosage of 
1 µg/ml, addition of AZD1775 did not further 
increase γH2AX positive cells, indicating that 
cells had reached their maximum potential for 
DNA damage. A dose-dependent increase in 
γH2AX positive cells was observed for the combi-
nation of CHOP with AZD1775 in SUDHL-10, 
which was most prominent in the range 500 nM 
AZD1775 to 1 µg/ml CHOP, producing a signifi-
cant increase in γH2AX positive cells (from 1% to 
40%; p = 0.0003). These findings demonstrate 
that the combination of a suboptimal dose of 
AZD1775 together with a suboptimal dose of 
either RT or CHOP leads to a strongly increased 
level of DNA damage.
Following up these results, we next performed 
protein analysis of the DDR kinases, checkpoint 
kinase 1 (CHK1) and checkpoint kinase 2 
(CHK2), which are activated in response to sin-
gle-stranded DNA breaks and double-stranded 
DNA breaks, respectively.18 Treatment of the 
cell lines SUDHL-5 (Figure 3a), SUDHL-6 
(Figure 3b) and SUDHL-10 (Figure 3c) with 
AZD1775 or RT alone for 3 h increased phos-
pho-CHK1 levels (Ser345). These effects were 
more prominent when RT was combined with 
AZD1775. Although no induction of phospho-
CHK1 was observed in response to CHOP 
monotherapy, an increase was observed combi-
nation with AZD1775. In SUDHL-5, protein 
levels of phospho-CHK2 (Thr68) were increased 
MRW de Jong, M Langendonk et al.
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Figure 1. AZD1775 combination therapy with radiation therapy (RT) or CHOP in DLBCL cell lines. 
(a) IC50 values are plotted for DLBCL cell lines treated with AZD1775 alone (blue), together with either 2 gray (red) or 4 gray 
(green) ionizing radiation; (b) IC50 values are plotted for DLBCL cell lines treated with AZD1775 alone (blue), together with 
0.01 µg/mL CHOP (red), with 0.1 µg/mL CHOP (green) or with 1 µg/mL CHOP (purple); (c) IC50 values were determined from 
metabolic activity data measured after 72 hours of treatment using resazurin Data were normalized to the control and 
plotted as the mean IC50 of n=3; (d) Synergy of each combination was calculated as the difference between the expected 
effect; (e) compared to the observed effect (O) of the combination therapy, with a corresponding (significant) p-value, 
analysed for significance using a one-sample T-test. Colours represent additive in white (E=O), synergy in green (E<O) and 
antagonism in red (E>O).
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(Figure 3a) upon treatment with RT and CHOP 
monotherapy, however no further increase was 
observed by addition of AZD1775. In the cell 
line SUDHL-6 (Figure 3b) treatment with RT 
strongly induced phospho-CHK2, whereas little 
effect was observed by CHOP chemotherapy. 
Addition of AZD1775 had little additional effect. 
In cell line SUDHL-10 (Figure 3c), only a mild 
phospho-CHK2 induction was observed upon 
RT or CHOP treatment, whereas addition of 
AZD1775 to RT strongly enhanced phospho-
CHK2 expression.
In all three cell lines mentioned above, treatment 
with AZD1775 led to a significant reduction in 
phospho-CDC2 (Tyr15; pCDC2) levels, the 
downstream target of WEE1, indicating that 
WEE1 kinase activity was reduced but without an 
effect on WEE1 protein levels. In conclusion, 
these data show activation of both CHK1 and 
CHK2 DDR pathways, indicating that the com-
bination of AZD1775 with RT or CHOP induces 
harmful DNA damage. Combined protein and 
γH2AX results show that while monotherapy with 
AZD1775, radiation or CHOP can activate the 
Figure 2. DNA damage analysis of AZD1775 combined with RT or CHOP. 
(a) Analysis of γH2AX positive cells in the cell lines SUDHL-5, SUDHL-6 and SUDHL-10 treated for 24 hours with 100 nM 
and 500 nM AZD1776 combined with 2 gray or 4 gray radiation therapy (RT); (b) Analysis of γH2AX positive cells in SUDHL-5, 
SUDHL-6 and SUDHL-10 treated for 24 hours with 100 nM and 500 nM AZD1776 combined with 0.1 or 1 µg/mL CHOP. Data 
are plotted as the mean ± SD of n=3. Statistical analysis was performed using a one-sample T-test (*p⩽0.05) (**p⩽0.01) 
(***p⩽0.001).
MRW de Jong, M Langendonk et al.
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DDR (phospho-CHK1 and phospho-CHK2) in 
response to treatment, the combination of RT or 
CHOP with AZD1775 is much more effective in 
inducing high levels of DNA damage.
AZD1775 abrogates mitotic arrest and induces 
premature mitotic entry
We next studied the effect of AZD1775, RT or 
CHOP monotherapy and combination therapy 
on cell cycle distribution and premature mitotic 
entry, measured as phospho-H3 (Ser10) positive 
cells in S-phase (Figure 4). Cell cycle analysis in 
the cell lines SUDHL-5, SUDHL-6 and SUDHL-
10 showed that monotherapy with radiation 
induced a significant dose-dependent increase in 
the percentage of G2/M phase cells, which was 
most prominent in SUDHL-10 (with an increase 
from 21% to 80%; p = 0.0047) after 4 Gy radia-
tion (Figure 4a). The addition of AZD1775 
induced a dose-dependent reduction in the per-
centage of G2/M phase cells (decreased from 
80% to 46%; p = 0.0025), an effect also observed 
in SUDHL-5 and SUDHL-6 (Figure 4a). These 
cell cycle data were linked to the data on phos-
pho-H3 positive cells, which normally occurs 
during mitosis, but can be observed during 
S-phase in the situation or premature mitotic 
entry. Analysis of phospho-H3 positive cells in 
S-phase revealed that AZD1775 treatment sig-
nificantly increased premature mitosis in 
SUDHL-5 (p = 0.0132), and SUHDL-10 
(p = 0.0008) and a trend for SUDHL-6 
(p = 0.0842) compared with control cells, while 
no effect was observed for RT monotherapy 
(Figure 4b). Moreover, levels of premature 
mitotic entry were increased in the cell lines 
SUDHL-5 and SUDHL-6 when AZD1775 was 
combined with RT, although the changes were 
not statistically significant. Together, these data 
indicate that addition of AZD1775 to RT 
reduces the G2/M arrest induced by RT, by 
allowing these cells to re-enter the cell cycle, but 
at the same time are likely over-stimulating cell 
cycle progression by facilitating premature 
mitotic entry. Cell cycle analysis of CHOP mon-
otherapy showed little effect for CHOP at 0.1 µg/
ml, whereas CHOP treatment at 1 µg/ml signifi-
cantly increased the percentage of G2/M phase 
cells in SUDHL-5 (p = 0.0040), SUDHL-6 
(p = 0.0349) and SUDHL-10 (p = 0.0237) 
(Figure 4c). However, no rescue of the CHOP-
induced G2/M arrest was observed when CHOP 
was combined with AZD1775, like was 
Figure 3. Protein analysis of the DNA damage 
response after treatment with AZD1775 in 
combination with RT or CHOP. 
Western blot analysis of WEE1, pCDC2 (Tyr15), pCHK1 
(Ser345), CHK1, pCHK2 (Thr68), CHK2, pH3 (Ser10), H3 and 
GAPDH protein levels in the (a) HL-5; b)DHL-6, and (c) L-10 
cell lines treated with 500 nM AZD1775, 4 gray RT and 1 µg/
mL CHOP for 3 hours.
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previously observed for the combination of 
AZD1775 with RT (Figure 4a). Analysis of pre-
mature positive phospho-H3 cells revealed a 
dose-dependent increase in premature mitotic 
entry when cells were treated with AZD1775 or 
when AZD1775 was combined with CHOP, 
while no effect was observed for CHOP alone 
(Figure 4d). In SUDHL-5, a strong decrease was 
observed in phospho-H3 cells treated with 1 µg/
ml CHOP, which was caused by a strong induc-
tion of DNA damage (Figure 2b) and cell death 
(Figure 1). Taken together, these data indicate 
that RT likely induces G2/M phase arrest to allow 
DNA repair, which is abrogated by addition of 
AZD1775, resulting in premature mitotic entry 
and increased DNA damage. A different effect 
can be observed for the combination of AZD1775 
with CHOP, in which the combination of CHOP 
with AZD1775 does not rescue the CHOP-
induced G2/M phase arrest. This difference is 
likely caused by the multiple detrimental effect 
of the CHOP compounds attacking the tubulin 
network and/or the DNA structure, resulting in 
structural damage and irreversible cell cycle 
arrest, accompanied by high levels of DNA 
damage.
Radiation, cyclophosphamide and doxorubicin 
enhance WEE1 protein expression
To further investigate the effect of RT or CHOP 
treatment, with or without AZD1775, on WEE1 
kinase activity, we performed protein analysis in 
the cell line SUDHL-10 treated with the respec-
tive CHOP compounds for 24 h (Figure 5a–b). 
Protein analysis showed that RT led to an 
increased pCDC2 level, indicating increased 
WEE1 activity, which was subsequently reduced 
to control levels on addition of AZD1775 (Figure 
5a). This analysis suggests that upregulated 
WEE1 activity acts to control RT-induced DNA 
damage, as observed by the increased γH2AX 
levels measured by flow cytometry (Figure 2a) 
and DDR activation by western blot (Figure 3a). 
No changes in pCDC2 levels were observed 
upon CHOP monotherapy treatment (Figure 
5a). We next investigated the effect of individual 
CHOP components on WEE1 protein activity, 
treating cells with each distinct component at 
the concentration used in 1 µg/ml CHOP or at a 
concentration that was 10/100/1000-fold higher. 
The individual compounds present in 1 µg/ml 
CHOP were 0.1 µM doxorubicin, 1.8 nM vin-
cristine and 3.17 µM cyclophosphamide, all of 
which are below clinical Cmax dosages.19 
Cyclophosphamide monotherapy at low non-
toxic dosages increased WEE1, pCDC2 and 
γH2AX protein levels in a dose-dependent man-
ner, while toxic treatment at 30 mM reduced 
both WEE1 and pCDC2 protein levels (Figure 
5c). Similarly, doxorubicin monotherapy 
induced a strong dose-dependent increase of 
pCDC2 and γH2AX levels compared with con-
trol cells, which was absent in cells treated with 
a toxic concentration of 10 µM (Figure 5c). 
Unlike cyclophosphamide and doxorubicin, 
Figure 5. Figure 5. WEE1 protein activity analysis 
after treatment with radiation, CHOP or doxorubicin, 
vincristine and cyclophosphamide monotherapy. 
(a) Western blot analysis of WEE1, pCDC2 (Tyr15), γH2AX 
and GAPDH protein levels in SUDHL-10 treated with 
AZD1775 in combination with 4 gray RT or 1 µg/mL 
CHOP for 24 hours; (b) Western blot analysis of WEE1, 
pCDC2 (Tyr15) and γH2AX in SUDHL-10 treated with an 
increasing concentration of doxorubicin and vincristine 
for 24 hours; (c) Western blot analysis of WEE1, pCDC2 
(Tyr15) and γH2AX in SUDHL-10 treated with an increasing 
concentration of cyclophosphamide for 24 hours. 
SUDHL-10 cells were treated with a 10-fold increasing 
concentration of each compound, the lowest concentration 
of which (0.1 µM doxorubicin, 1.8 nM vincristine and 3.17 
µM cyclophosphamide) was used in the 1 µg/mL CHOP 
treatment.
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vincristine monotherapy actually reduced both 
pCDC2 and WEE1 protein levels at the low 
1.8 nM dose, while upregulating γH2AX protein 
levels (Figure 5c). These data show that although 
cyclophosphamide and doxorubicin are able to 
increase WEE1 activity, these changes are likely 
suppressed by the presence of vincristine in 
CHOP, thereby counteracting the upregulation 
of the WEE1 protein.
Doxorubicin and vincristine enhance AZD1775-
induced cell killing
Pursuing the finding that certain CHOP compo-
nents can upregulate WEE1 protein expression, 
we next determined if single CHOP components 
(cyclophosphamide, doxorubicin or vincristine) 
complement AZD1775 treatment in the SUDHL-
10 cell line. Cyclophosphamide treatment alone 
or in combination with AZD1775 had no effect 
on metabolic activity, indicating that the concen-
trations used were too low to affect viability 
(Figure 6a). Doxorubicin treatment combined 
with 500 nM AZD1775 significantly reduced 
metabolic activity (from 88% to 32%; p = 0.0023), 
indicating that upregulation of WEE1 protein by 
doxorubicin enhanced sensitivity to AZD1775 
(Figure 6c). Single agent treatment with vincris-
tine decreased metabolic activity by 91% com-
pared with control, with no additional effect of 
AZD1775 (Figure 6b).
Analysis of the cell cycle showed that both doxo-
rubicin and vincristine monotherapy increased 
the percentage of G2/M phase cells, while no 
effect was observed for cyclophosphamide (Figure 
6d). Similar to previous results, addition of 
AZD1775 decreased G2/M percentages, indicat-
ing premature mitotic entry.
Analysis of γH2AX showed that doxorubicin 
monotherapy induced minimal γH2AX positive 
cells, but addition of AZD1775 significantly 
increased γH2AX from 2% to 13% (p = 0.0083) 
(Figure 6e). Vincristine was particularly effective 
in inducing DNA damage, especially in combina-
tion with AZD1775 (γH2AX increased from 31% 
to 43%). Remarkably, the DNA damaging effect 
of vincristine was lost in CHOP chemotherapy, 
since CHOP only induced 5% γH2AX positive 
cells compared with 31% γH2AX positive cells 
induced by vincristine. Nevertheless, the combi-
nation of AZD1775 with CHOP resulted in a sig-
nificant increase in γH2AX levels (5–38% with 
p = 0.0092), similar to the levels achieved by vin-
cristine alone (31%) or vincristine combined with 
AZD1775 (43%). Taken together, these results 
demonstrate the potential of chemotherapeutic 
agents such as cyclophosphamide and doxoru-
bicin as inducers of WEE1 protein expression, 
potentially making them suitable for use in com-
bination with AZD1775 in other cancers besides 
DLBCL.
Discussion
We presented highly robust data showing that the 
combination of the WEE1 inhibitor AZD1775 
with RT or CHOP chemotherapy results in 
increased levels of DNA damage, activation of the 
DDR pathways and induction of premature 
mitotic entry, leading to synergistic lethality of 
DLBCL cells. Moreover, protein analysis revealed 
that RT, cyclophosphamide and doxorubicin all 
effectively increased WEE1 protein expression, 
indicating that these agents might be suitable for 
use in combination treatments with AZD1775.
The WEE1 tyrosine kinase plays an essential role 
in maintaining genomic stability by allowing 
DNA damage repair at the G2/M transition. 
Activation of WEE1 by CHK1 is a key mecha-
nism preventing cell cycle progression during 
DNA damage repair.10 As DLBCL is a cancer 
with high levels of genomic instability13 and DNA 
damage,14 DLBCL cells rely heavily on check-
point activation and DNA damage repair, which 
are effectively prevented by blocking WEE1. 
Furthermore, inhibition of CDC2/CDK1 by 
WEE1 during S-phase allows DNA replication 
and stabilization of replication forks, which 
become hazardous in the event of WEE1 inhibi-
tion.20 In tumour cells lacking a mechanism for 
repair in G1/S phase as a result of TP53 muta-
tion, cell cycle arrest and repair at the G2/M 
phase checkpoint is especially important21 These 
factors all contribute to making WEE1 an attrac-
tive target for inhibitor therapy in either TP53-
deficient tumours or together with genotoxic 
therapy to either enhance DNA damage induc-
tion or block DNA damage repair. However, we 
found that TP53 mutation status did not deter-
mine sensitivity to the WEE1 inhibitor AZD1775 
in our DLBCL cell lines, a finding that contra-
dicts current literature in non-small cell lung can-
cer17 and ovarian adenocarcinoma tumour cells.15 
However, other studies in acute myeloid leuke-
mia (AML) have shown that TP53 does not 
Therapeutic Advances in Hematology 11
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determine therapy outcome with AZD1775,22,23 
indicating possible differences between solid 
tumours and hematologic malignancies.
High levels of synergism and DNA damage were 
observed across multiple cell lines, likely due to 
the high levels of genomic instability and DNA 
damage outweighing the presence of TP53 in 
DLBCL.
Chemotherapy in combination with AZD1775 
has been shown to be synergistic together with 
compounds such as doxorubicin in colon cancer 
cell lines24 and B-cell lymphoma cell lines,25 with 
cytarabine in B-cell lymphoma cell lines and xen-
ograft mouse models,25 vincristine in B-cell and 
T-cell leukaemia cell lines and patient cells,26 
cyclophosphamide-like compounds in lympho-
blastoid cell lines and rhabdomyosarcoma cell 
lines27,28 and with paclitaxel in breast cancer.29 
Similarly, combined WEE1 inhibition and RT 
has proven successful in gliomas and osteosar-
coma.30,31 Recently, Wang and colleagues showed 
that the efficacy of doxorubicin with AZD1775 
was dependent on the moment of cell cycle arrest 
induced by doxorubicin, with combination ther-
apy proving highly effective in G2/M phase-
arrested lymphoma cell lines but not in 
G1/S-phase-arrested cells.26 At the same time, 
doxorubicin was also shown to influence WEE1 
and pCDC2 levels based on TP53 status in a 
time-dependent manner in melanoma cell lines. 
In TP53 wild type cells, doxorubicin induced a 
steady increase over the first 1–9 h after treat-
ment, but both WEE1 and pCDC2 levels declined 
at 24 h. By contrast, pCDC2 levels steadily 
increased in TP53 mutant cells after treatment, 
even at 24 h.32 A comparable synergy with 
AZD1775 was shown for ionizing radiation, 
which causes predominantly single stranded 
DNA breaks,33 leading to ATR activation and 
downstream phosphorylation and activation of 
CHK1.34,35 Since CHK1 is one of the most 
important positive regulators of WEE1,10 any 
activation of the ATR-CHK1 axis will likely result 
in increased activation of WEE1 and will likely 
benefit from AZD1775 combination treatment. 
We found enhanced toxicity for combinations of 
AZD1775 with RT, CHOP and single agent dox-
orubicin, which all resulted in G2/M arrest, 
increased WEE1 protein levels and high levels of 
DNA damage. Based on current evidence, syn-
ergy with AZD1775 seems likely when a treat-
ment induces either: (a) G2/M arrest, (b) WEE1 
upregulation, (c) activation of the DDR, or (d) all 
of the above. An exception to this rule was vin-
cristine combined with AZD1775, as vincristine 
led to decreased protein levels of WEE1 and 
pCDC2. Visconti and colleagues showed that at 
the spindle assembly checkpoint during mitosis, 
WEE1 promotes survival when cells are under 
pressure from anti-microtubule cancer drugs or 
malformed spindles, and that this checkpoint is 
only restored through genetic or chemical inhibi-
tion of WEE1. In line with their hypothesis, 
Visconti and colleagues found synergism for the 
combination of vincristine and AZD1775, but no 
downregulation of WEE1 protein was observed 
upon treatment with 25 nM vincristine.27 
Although vincristine reduced WEE1 protein lev-
els in our DLBCL cell line, these effects are likely 
counteracted by induction of WEE1 by doxoru-
bicin and cyclophosphamide, therefore maintain-
ing high levels of toxicity and synergism with 
AZD1775 in the CHOP combination.
In conclusion, we demonstrated that AZD1775 
combined with RT and CHOP effectively inhibits 
WEE1 and is synergistic in multiple cell lines. 
Based on protein, cell cycle and DNA damage 
analysis, we predict that AZD1775 will be a 
highly effective treatment in combination with 
other (chemo) therapeutic compounds that 
induce either WEE1 upregulation, G2/M arrest 
or activation of the DDR. These data underline 
the considerable potential of WEE1 inhibition in 
the clinical setting and help pave the way for the 
application of AZD1775 and chemotherapeutic 
combination therapies in other cancer types.
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